已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml

医学 前列腺癌 前列腺特异性抗原 泌尿科 前列腺切除术 前列腺 肿瘤科 内科学 癌症
作者
Kazuto Ito,Akira Yokomizo,Tetsuo Shoji,Gaku Arai,Mikio Sugimoto,Koichiro Akakura,Hisashi Hasumi,Hideki Sakai,Akiko Ouraji,Ryosuke Oki,Eiji Kashiwagi,Yoshitomo Kobori,Hiromi Hirama,Hiroki Kitoh,Hiroji Uemura,Tomoaki Hakariya,Kazuhiro Suzuki
出处
期刊:The Journal of Urology [Ovid Technologies (Wolters Kluwer)]
卷期号:203 (1): 83-91 被引量:4
标识
DOI:10.1097/ju.0000000000000495
摘要

No AccessJournal of UrologyAdult Urology1 Jan 2020Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml Kazuto Ito, Akira Yokomizo, Shoji Tokunaga, Gaku Arai, Mikio Sugimoto, Koichiro Akakura, Hisashi Hasumi, Hideki Sakai, Akiko Ouraji, Ryo Oki, Eiji Kashiwagi, Yoshitomo Kobori, Hiromi Hirama, Hiroki Kitoh, Hiroji Uemura, Tomoaki Hakariya, and Kazuhiro Suzuki Kazuto ItoKazuto Ito *Correspondence: Institute for Preventive Medicine, Kurosawa Hospital, 187, Yanaka-cho, Takasaki, Gunma 370-1203, Japan telephone: +81-27-352-1166; FAX: +81-27-352-7925; E-mail Address: [email protected] Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan Institute for Preventive Medicine, Kurosawa Hospital, Takasaki, Japan Financial interest and/or other relationship with Takeda Pharmaceutical Company, Janssen Pharmaceutical, Astellas Pharma and AstraZeneca. More articles by this author , Akira YokomizoAkira Yokomizo Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Urology, Hara-Sanshin Hospital, Fukuoka, Japan Financial interest and/or other relationship with Astellas Pharma, AstraZeneca, Bayer Yakuhin, Janssen Pharmaceutical, Sanofi Genzyme and Takeda Pharmaceutical. More articles by this author , Shoji TokunagaShoji Tokunaga Medical Information Center, Kyushu University Hospital, Fukuoka, Japan More articles by this author , Gaku AraiGaku Arai Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan More articles by this author , Mikio SugimotoMikio Sugimoto Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan More articles by this author , Koichiro AkakuraKoichiro Akakura Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo, Japan More articles by this author , Hisashi HasumiHisashi Hasumi Yokohama City University, Yokohama, Japan More articles by this author , Hideki SakaiHideki Sakai Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan Financial interest and/or other relationship with Astellas Pharma, AstraZeneca, Bayer Yakuhin, Janssen Pharmaceutical and Takeda Pharmaceutical. More articles by this author , Akiko OurajiAkiko Ouraji Clinical Research Support Center Kyushu, Fukuoka, Japan More articles by this author , Ryo OkiRyo Oki Institute for Preventive Medicine, Kurosawa Hospital, Takasaki, Japan More articles by this author , Eiji KashiwagiEiji Kashiwagi Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan More articles by this author , Yoshitomo KoboriYoshitomo Kobori Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan More articles by this author , Hiromi HiramaHiromi Hirama Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan More articles by this author , Hiroki KitohHiroki Kitoh Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo, Japan More articles by this author , Hiroji UemuraHiroji Uemura Yokohama City University, Yokohama, Japan More articles by this author , Tomoaki HakariyaTomoaki Hakariya Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan More articles by this author , and Kazuhiro SuzukiKazuhiro Suzuki Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan More articles by this author and Members of PROPHET View All Author Informationhttps://doi.org/10.1097/JU.0000000000000495AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The PROPHET (Prostate Cancer: Prostate Health Index Trial) is a prospective study to clarify the diagnostic impact of laboratory based and prostate volume adjusted p2PSA ([–2] proenzyme prostate specific antigen) related indexes on prostate cancer and clinically significant prostate cancer with prostate specific antigen less than 10 ng/ml. Materials and Methods: Between April 2015 and March 2017, 421 men 50 to 79 years old in the prostate specific antigen range above age specific cutoffs and below 10 ng/ml were registered in the PROPHET. We investigated the diagnostic impacts of various clinical laboratory based free prostate specific antigen related and p2PSA related indexes on any grade and high Gleason grade group prostate cancer. Results: Of the 363 eligible participants 179, 141 and 80 were diagnosed with any grade, and Gleason Grade Group 2-5 and 3-5 prostate cancer, respectively. The AUC-ROCs distinguishing nonprostate cancer vs prostate cancer, nonprostate cancer plus low Gleason Grade Group and low volume vs remaining prostate cancer with a higher Gleason Grade group or a higher volume on the PHI (Prostate Health Index) were significantly superior to the AUC-ROCs of prostate specific antigen and free-to-total prostate specific antigen. At 90% sensitivity in all investigated p2PSA related indexes the false-positive rate was superior to that of prostate specific antigen and free-to-total prostate specific antigen in any group comparison in terms of the Gleason Grade Group and positive biopsy cores. In 35% to 42% of men without prostate cancer and/or those with less aggressive prostate cancer the PHI would avoid unnecessary biopsy. Conclusions: Laboratory based p2PSA related indexes were significantly superior for detecting clinically significant prostate cancer compared to free-to-total prostate specific antigen. The indexes those would avoid up to 42% of prostate biopsies in men without aggressive cancer while maintaining 90% sensitivity. References 1. : Prostate cancer in Asian men. Nat Rev Urol 2014; 11: 197. Google Scholar 2. : Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screening. Int J Cancer 2018; 143: 1611. Google Scholar 3. : Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol 2011; 18: 876. Google Scholar 4. : Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy. Int J Urol 2009; 16: 561. Google Scholar 5. : Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range. World J Urol 2013; 31: 305. Google Scholar 6. : The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol 2014; 46: 711. Google Scholar 7. : Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013; 111: 928. Google Scholar 8. : Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries. Int J Urol 2015; 22: 334. Google Scholar 9. : Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen. Int J Clin Oncol 2014; 19: 782. Google Scholar 10. : The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40: 244. Google Scholar 11. : A receiver operating characteristic partial area index for highly sensitive diagnostic tests. Radiology 1996; 201: 745. Google Scholar 12. : Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027. Google Scholar 13. : Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725. Google Scholar 14. : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320. Google Scholar 15. : Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310. Google Scholar 16. : Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. U.S. Preventive Services Task Force. Ann Intern Med 2012; 157: 120. Google Scholar 17. : Screening for prostate cancer: history, evidence, controversies and future perspectives toward individualized screening. Int J Urol 2019; doi: 10.1111/iju.14039. Crossref, Google Scholar 18. : Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology Position in 2019. Eur Urol 2019; 76: 142. Google Scholar 19. : The impact of baseline [−2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 2014; 140: 257. Google Scholar 20. : Importance of [–2] proPSA measurement in a diagnosis of PROstate cancer: Prostate HEalth index Trial (PROPHET) - diagnostic impacts of prostate volume-adjusted indices on Gleason grade group >=2 or >=3 cancer (abstract PD06-06). J Urol, suppl., 2018; 199: e152. Link, Google Scholar The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. Supported by the Clinical Research Support Center Kyushu, Fukuoka, Japan. No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue 1January 2020Page: 83-91Supplementary Materials Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.Keywordshematologic testsprostate-specific antigenmass screeningenzyme precursorsprostatic neoplasmsMetricsAuthor Information Kazuto Ito Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan Institute for Preventive Medicine, Kurosawa Hospital, Takasaki, Japan *Correspondence: Institute for Preventive Medicine, Kurosawa Hospital, 187, Yanaka-cho, Takasaki, Gunma 370-1203, Japan telephone: +81-27-352-1166; FAX: +81-27-352-7925; E-mail Address: [email protected] Financial interest and/or other relationship with Takeda Pharmaceutical Company, Janssen Pharmaceutical, Astellas Pharma and AstraZeneca. More articles by this author Akira Yokomizo Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Department of Urology, Hara-Sanshin Hospital, Fukuoka, Japan Financial interest and/or other relationship with Astellas Pharma, AstraZeneca, Bayer Yakuhin, Janssen Pharmaceutical, Sanofi Genzyme and Takeda Pharmaceutical. More articles by this author Shoji Tokunaga Medical Information Center, Kyushu University Hospital, Fukuoka, Japan More articles by this author Gaku Arai Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan More articles by this author Mikio Sugimoto Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan More articles by this author Koichiro Akakura Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo, Japan More articles by this author Hisashi Hasumi Yokohama City University, Yokohama, Japan More articles by this author Hideki Sakai Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan Financial interest and/or other relationship with Astellas Pharma, AstraZeneca, Bayer Yakuhin, Janssen Pharmaceutical and Takeda Pharmaceutical. More articles by this author Akiko Ouraji Clinical Research Support Center Kyushu, Fukuoka, Japan More articles by this author Ryo Oki Institute for Preventive Medicine, Kurosawa Hospital, Takasaki, Japan More articles by this author Eiji Kashiwagi Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan More articles by this author Yoshitomo Kobori Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan More articles by this author Hiromi Hirama Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan More articles by this author Hiroki Kitoh Japan Community Healthcare Organization Tokyo Shinjuku Medical Center, Tokyo, Japan More articles by this author Hiroji Uemura Yokohama City University, Yokohama, Japan More articles by this author Tomoaki Hakariya Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan More articles by this author Kazuhiro Suzuki Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan More articles by this author Expand All The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. Supported by the Clinical Research Support Center Kyushu, Fukuoka, Japan. No direct or indirect commercial, personal, academic, political, religious or ethical incentive is associated with publishing this article. Advertisement PDF downloadLoading ...
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cheng完成签到 ,获得积分10
1秒前
彦子完成签到 ,获得积分10
1秒前
儿学化学打断腿完成签到,获得积分10
2秒前
乌拉拉啦啦啦完成签到 ,获得积分10
3秒前
xwwx完成签到 ,获得积分10
3秒前
GG完成签到,获得积分10
3秒前
华仔应助archer01采纳,获得10
4秒前
4秒前
SciGPT应助骑驴找马采纳,获得30
5秒前
西门浩宇完成签到 ,获得积分10
5秒前
高屋建瓴完成签到,获得积分10
5秒前
deeferf完成签到 ,获得积分10
5秒前
小羊咩完成签到 ,获得积分10
6秒前
6秒前
机灵白桃完成签到,获得积分20
7秒前
没钱搞什么学术完成签到 ,获得积分10
7秒前
小开发布了新的文献求助10
8秒前
楠茸完成签到 ,获得积分10
9秒前
Summer_Xia完成签到 ,获得积分10
9秒前
wu完成签到,获得积分10
10秒前
Dandy完成签到,获得积分10
11秒前
123完成签到 ,获得积分10
11秒前
黄涛涛发布了新的文献求助10
11秒前
资格丘二完成签到,获得积分10
11秒前
舒适的方盒完成签到 ,获得积分10
12秒前
SciGPT应助机灵白桃采纳,获得10
12秒前
克泷完成签到 ,获得积分10
13秒前
读懂文献就像喝水完成签到 ,获得积分10
13秒前
Skye完成签到 ,获得积分10
13秒前
结实的小土豆完成签到 ,获得积分10
13秒前
榆木小鸟完成签到 ,获得积分10
13秒前
asdfqwer完成签到 ,获得积分0
14秒前
害羞龙猫完成签到 ,获得积分10
14秒前
SCI的芷蝶完成签到 ,获得积分10
14秒前
努力的咩咩完成签到 ,获得积分10
14秒前
zoele完成签到 ,获得积分10
14秒前
铜离子完成签到 ,获得积分10
14秒前
NEO完成签到 ,获得积分10
15秒前
赘婿应助wu采纳,获得10
15秒前
超级月光完成签到,获得积分10
16秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Population Genetics 3000
Continuum thermodynamics and material modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Theory of Block Polymer Self-Assembly 750
지식생태학: 생태학, 죽은 지식을 깨우다 700
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3497285
求助须知:如何正确求助?哪些是违规求助? 3081852
关于积分的说明 9169340
捐赠科研通 2774991
什么是DOI,文献DOI怎么找? 1522692
邀请新用户注册赠送积分活动 706207
科研通“疑难数据库(出版商)”最低求助积分说明 703234